Archives of physical medicine and rehabilitation · 2026
Effect of Albuterol Repetabs on Pulmonary Function in Individuals With Chronic Spinal Cord Injury.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Panza Gino S, La Fountaine Michael F, Sutor Tommy W, Cirnigliaro Christopher M, Green Douglas, Kirshblum Steven C, Hobson Joshua, Wecht Jill M, Radulovic Miroslav, Delgado Andrew D, Bauman William A, Schilero Gregory J
Аннотация
OBJECTIVE: To determine the effect of 12 weeks of twice daily albuterol repetabs on pulmonary function in persons with chronic spinal cord injury.
DESIGN: Twelve-week prospective, double-blinded, placebo-controlled trial.
SETTING: Research laboratories.
PARTICIPANTS: Thirty two individuals (N=32) with chronic spinal cord injury.
INTERVENTIONS: Albuterol repetabs or placebo, twice daily, for 12 weeks.
MAIN OUTCOME MEASURES: Pulmonary function tests and maximum inspiratory and expiratory pressures.
RESULTS: Interaction effects were found for expiratory reserve volume and forced expiratory volume. Improvements in the drug group were found for total lung capacity, vital capacity, expiratory reserve volume, and maximal inspiratory pressure. Forced expiratory volume in 1 second did not change in the drug group but trended toward a significant decrease in the placebo group.
CONCLUSIONS: Twelve weeks of albuterol treatment improved overall pulmonary function and ventilatory muscle strength, compared to placebo, in those living with spinal cord injury.
DESIGN: Twelve-week prospective, double-blinded, placebo-controlled trial.
SETTING: Research laboratories.
PARTICIPANTS: Thirty two individuals (N=32) with chronic spinal cord injury.
INTERVENTIONS: Albuterol repetabs or placebo, twice daily, for 12 weeks.
MAIN OUTCOME MEASURES: Pulmonary function tests and maximum inspiratory and expiratory pressures.
RESULTS: Interaction effects were found for expiratory reserve volume and forced expiratory volume. Improvements in the drug group were found for total lung capacity, vital capacity, expiratory reserve volume, and maximal inspiratory pressure. Forced expiratory volume in 1 second did not change in the drug group but trended toward a significant decrease in the placebo group.
CONCLUSIONS: Twelve weeks of albuterol treatment improved overall pulmonary function and ventilatory muscle strength, compared to placebo, in those living with spinal cord injury.